BRPI0716815A2 - Co posto heteroatomáticos tendo atividade biológia agonista e/ou antagonista de receptor de esfinfosina-1-fosfato (s1p) - Google Patents

Co posto heteroatomáticos tendo atividade biológia agonista e/ou antagonista de receptor de esfinfosina-1-fosfato (s1p)

Info

Publication number
BRPI0716815A2
BRPI0716815A2 BRPI0716815-2A2A BRPI0716815A BRPI0716815A2 BR PI0716815 A2 BRPI0716815 A2 BR PI0716815A2 BR PI0716815 A BRPI0716815 A BR PI0716815A BR PI0716815 A2 BRPI0716815 A2 BR PI0716815A2
Authority
BR
Brazil
Prior art keywords
spinphosine
heteroatomatic
agonist
phosphate
receiver
Prior art date
Application number
BRPI0716815-2A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Richard L Beard
John E Donello
Haiqing Yuan
Xiaoxia Liu
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0716815A2 publication Critical patent/BRPI0716815A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
BRPI0716815-2A2A 2006-09-07 2007-09-05 Co posto heteroatomáticos tendo atividade biológia agonista e/ou antagonista de receptor de esfinfosina-1-fosfato (s1p) BRPI0716815A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82480706P 2006-09-07 2006-09-07
PCT/US2007/077588 WO2008030843A1 (en) 2006-09-07 2007-09-05 Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity

Publications (1)

Publication Number Publication Date
BRPI0716815A2 true BRPI0716815A2 (pt) 2013-11-05

Family

ID=38961939

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716815-2A2A BRPI0716815A2 (pt) 2006-09-07 2007-09-05 Co posto heteroatomáticos tendo atividade biológia agonista e/ou antagonista de receptor de esfinfosina-1-fosfato (s1p)

Country Status (6)

Country Link
EP (1) EP2066633A1 (ja)
JP (1) JP2010504286A (ja)
AU (1) AU2007292347A1 (ja)
BR (1) BRPI0716815A2 (ja)
CA (1) CA2662852A1 (ja)
WO (1) WO2008030843A1 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005014271A1 (de) * 2005-03-24 2006-09-28 Rhein Chemie Rheinau Gmbh Mikrogele in Kombination mit funktionalen Additiven
WO2008141013A1 (en) * 2007-05-08 2008-11-20 Allergan, Inc. S1p3 receptor inhibitors for treating pain
KR20190004843A (ko) 2008-07-23 2019-01-14 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[b]인돌-3-일)아세트산 유도체
BRPI0917923B1 (pt) 2008-08-27 2022-04-05 Arena Pharmaceuticals Inc Derivado de ácido tricíclico substituído, sua composição, seu uso e processo para preparar a referida composição
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
US8741875B2 (en) 2009-11-24 2014-06-03 Allergan, Inc. Compounds as receptor modulators with therapeutic utility
NZ599966A (en) 2009-11-24 2014-09-26 Allergan Inc Novel compounds as receptor modulators with therapeutic utility
EP3378854B1 (en) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
JP2013521301A (ja) 2010-03-03 2013-06-10 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体修飾物質およびその結晶形の調製のためのプロセス
WO2011133734A1 (en) 2010-04-23 2011-10-27 Bristol-Myers Squibb Company 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
US8513220B2 (en) 2010-05-14 2013-08-20 Allergan, Inc. Aromatic compounds having sphingosine-1-phosphonate (S1P) receptor activity
US20110281822A1 (en) 2010-05-14 2011-11-17 Allergan, Inc. Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity
CN103237795B (zh) 2010-09-24 2015-10-21 百时美施贵宝公司 经取代的噁二唑化合物及其作为s1p1激动剂的用途
CA2933250A1 (en) 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CN116850181A (zh) 2015-01-06 2023-10-10 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
MX2017016530A (es) 2015-06-22 2018-03-12 Arena Pharm Inc Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1).
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
KR20210074291A (ko) 2018-09-06 2021-06-21 아레나 파마슈티칼스, 인크. 자가면역 및 염증성 장애의 치료에 유용한 화합물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665159B1 (fr) * 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
JPH06501926A (ja) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
CA2547198A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists

Also Published As

Publication number Publication date
EP2066633A1 (en) 2009-06-10
AU2007292347A1 (en) 2008-03-13
CA2662852A1 (en) 2008-03-13
WO2008030843A1 (en) 2008-03-13
JP2010504286A (ja) 2010-02-12

Similar Documents

Publication Publication Date Title
BRPI0716815A2 (pt) Co posto heteroatomáticos tendo atividade biológia agonista e/ou antagonista de receptor de esfinfosina-1-fosfato (s1p)
LTPA2021502I1 (lt) Angiotenzino receptorių antagonisto ir NEP inhibitoriaus farmaciniai deriniai
BRPI0813580A2 (pt) Antagonistas de receptor 1 de hormônio de concentração de melanina não básicos e métodos
BRPI0815668A2 (pt) compostos pirrol tendo atividade biológica antagonista e agonista de receptor de esfingosina-1-fosfato.
BRPI1014877A8 (pt) compostos diamida tendo antagonista do receptor muscarínico e atividade agonista do receptor b2 adrenérgico.
BRPI0719184A2 (pt) Análise e gerenciamento de sistema
DK1615889T3 (da) Biphenylderivater med beta2-adrenergisk receptoragonist- og muscarinisk receptorantagonistaktivitet
DE602004018575D1 (de) Chirurgisches Ultraschallsystem und Probe
BRPI0808001A2 (pt) Dispositivo para monitoração de analisado revestido com polímero que contém nitrogênio heterocíclico e métodos de uso.
DE602005020738D1 (de) Ultraschallsonde
HK1132744A1 (en) Bruton's tyrosine kinase activity probe and method of using bruton's
BRPI0919539A2 (pt) antagonistas de receptor de opioide periférico e empregos dos mesmos
GB0611154D0 (en) Novel receptor antagonists and their methods of use
ATE420088T1 (de) Chinolinoncarbonsäureamidverbindungen als 5-ht4- rezeptoragonisten
BRPI0922483A2 (pt) agonista de receptor gpr120 e usos dos mesmos
BRPI0716732A2 (pt) sistema e/ou mÉtodo para aquisiÇço de sinais gnss
MA29557B1 (fr) Preparations de peptides agonistes du recepteur de l'erythropoietine et utilisations
EP1910795A4 (en) SYSTEM AND METHODS FOR NON-DESTRUCTIVE TESTING OF TUBULAR SYSTEMS
EP1789788A4 (en) IMMOBILIZED SAMPLES AND METHOD FOR DETECTING CONFORMATIVELY MODIFIED PRION PROTEINS
BRPI0806966A2 (pt) Combinação de um antagonista de receptor muscarínico e um agonista beta-2-adrenoceptor
DE602007010179D1 (de) Piperidinylaminopyridazine und ihre verwendung als schnelldissoziierende antagonisten des dopamin-2-rezeptors
BRPI1009257A2 (pt) antagonista receptor de mineralocorticoide e métodos de uso.
BRPI0719776A2 (pt) Preparação líquida aquosa tendo penetração de gatifloxacino intraocular melhorada
ITTO20040743A1 (it) Dispositivo omogeneizzatore monouso, e suo impiego per la preparazione di campioni omogeneizzati
ITRM20060176A1 (it) Procedimento di analisi e controllo multimediale dell attivita riabilitativa domiciliare e mezzi per la sua attuazione

Legal Events

Date Code Title Description
B08L Application fees: final archiving

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 5A, 6A E 7A ANUIDADES.

B08I Application fees: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 5A, 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.